Breast Cancer Research and Treatment **49**: 271–272, 1998.
© 1998 *Kluwer Academic Publishers. Printed in the Netherlands.*

Author index, Volume 49

Agrawal S 97
Aguiari G 227
Akashi-Tanaka S 79
Amadori D 209
Asselain B 219

Bailey-Penrod J 171
Baldini E 129
Barbarulo D 13
Barbier Y 135
Bastert G 145
Bélanger A 1
Bernoux A 219
Bobin JY 135
Bode S 145
Bracken SP 61
Brandes LJ 61
Brandt-Rauf PW 261
Breuer B 261
Budillon A 13

Candas B 1
Capasso I 13
Caponigro F 13
Caratení G 13
Cariello S 209
Carney WP 261
Casaretti R 13
Chang K-J 237
Chang Y-S 237
Chen Y-C 237
Cheng A-L 237
Chew K 155
Chiavacci F 129
Cho-Chung YS 97
Chung HC 41
Cody HS III 261
Comella G 13
Comella P 13
Cortese A 261

D'Aiuto G 13
Dalberg K 69
Daponte A 13
de Cremoux P 219
De Matteis A 209
del Senno L 227
Descotes F 135
Di Lieto M 129
Diel IJ 145

Edgerton S 261

Fathy El Etreby M 109
Ferrari M 209
Fioretto L 129
Florendo C 155
Frackelton AR Jr 119
Frasci G 13
Frassineti GL 209
Fukutomi T 79

Gentile A 13
Gollan Ch 145
Goodson WH III 155
Gravina A 13

Hasebe T 195
Hirohashi S 195
Holmberg E 27
Huang Y 251
Hultborn R 27

Jiang Z-F 251

Kim BS 41
Kim JH 41
Kim JJ 41
Kovařík J 27

Labrie C 1
Labrie F 1
Lainé-Bidron C 219
Lambertini E 227
Landys K 27
Lee KS 41
Li Y-B 251
Liang Y 109
Lin D-T 237
Lin J-F 237
Lin M-T 237
Liu X-Q 251
Ljung B-M 155
Lombardi A 209
Lui L-T 237
Luo S 1

Magdelénat H 219
Maiorino L 13
Martin EC 219
Mattsson A 69
Mayal B 155
McCulloch RK 165
Meyberg GC 145
Min JS 41
Minick R 261
Miyakawa K 79
Moore DH II 155
Mukai K 195
Mustacchi G 209

Nangia-Makker P 171
Nanni O 209
Nascimben O 209
Nomura Y 51
Nowak E 261

Osborne MP 261

Papadimitriou JM 165
Park JO 41
Park YG 97
Penolazzi L 227
Persson S 27
Piva R 227
Pratap R 35

Rha SY 41
Roh JK 41

Rutqvist LE 69

Saez S 135
Sandelin K 69
Santoro A 209
Sarkar FH 171
Sarvis R 171
Sauerbrei W 87
Scarpi E 209
Schmoor C 87
Schulgen G 87
Schumacher M 87
Sellner LN 165
Shimosato Y 195
Shirouzu M 51
Shousha S 35
Simmons R 261
Smith HS 155
Smith S 261
Solomayer E-F 145
Song S-T 251
Srivastava AR 97
Srivastava RK 97
Stevenson LE 119
Stoll BA 187

Takayama T 51
Tang J-L 237
Tang Z-M 251
Thomas R 13
Thor A 261
Tibaldi C 129
Tsubono Y 195
Tsuda H 195
Tsuda H 79
Turbett GR 165

Uchiyama N 79

Velanovich V 245
Ville G 135
Visscher DW 171

Waldman FM 155
Wallwiener D 145

Xu J-M 251

Yamamoto H 195
Yeh K-H 237
Yoo NC 41
Yu S-C 237

Zhou L 251
Zoli W 209

Breast Cancer Research and Treatment **49**: 273-275, 1998.
© 1998 *Kluwer Academic Publishers. Printed in the Netherlands.*

Subject index, Volume 49

adjuvant therapy
comparison of chemo, endocrine, and combined vs. ER, menopausal status 51-60
antiestrogens
EM-800 prevention of rat DMBA tumors 1-11
see also tamoxifen
antiprogestins
antitumor activity in vivo, especially with tamoxifen 109-117
antisense
depletion of protein kinase A induces apoptosis and growth arrest 97-107
apoptosis
induced by antisense depletion of protein kinase A subunit 97-107

bone density
effect of pure antiestrogen EM-800 1-11
bone marrow micrometastases
prognostic value of cathepsin D in 145-154
prognostic value of tumor cells by IHC in marrow biopsy 27-33
breast conservation
outcome of salvage treatments for recurrence 69-78
bromodeoxyuridine (BrdU) labelling index
functional relationship with Ki-67 proliferation index 155-164

cathepsin D
prognostic value in bone marrow micrometastases 145-154
chemosensitivity assay
using MTT assay in fresh breast cancer tissue 251-259
chemotherapy
comparison of adjuvant chemo, endocrine, and combined vs. ER, menopausal status 51-60
epirubicin/vinorelbine as first line therapy 129-134
high-dose, mobilization of PBSCs for support 237-244
in vitro sensitivity using the MTT assay 251-259
chemotherapy (continued)
lonidamine enhancement of doxorubicin responses 209-217
pilot trial of doxorubicin potentiation by histamine antagonist DPPE 61-68
weekly paclitaxel-cisplatin with G-CSF, phase II 13-26
cholesterol
reduction by pure antiestrogen EM-800 1-11
cisplatin
phase II study with paclitaxel, G-CSF 13-26
CT scan
in detection of intraductal spread 79-86

decoy strategy
double-stranded DNA decoys reduce ER gene expression 227-235
diagnostic imaging
value of contrast-enhanced CT scan for intraductal spread 79-86
diet
Western diet, early puberty, and breast cancer risk 187-193
DMBA rat mammary tumors
prevention by pure antiestrogen EM-800 1-11
doxorubicin
pilot trial of potentiation by histamine antagonist DPPE 61-68
response enhancement with lonidamine 109-217
DPPE (histamine antagonist)
potentiates doxorubicin effect in pilot trial 61-68

endocrine therapy
antitumor activity of tamoxifen enhanced with antiprogestins 109-117
comparison of adjuvant chemo, endocrine, and combined vs. ER, menopausal status 51-60
epirubicin
trial of combination with vinorelbine as first line therapy 129-134
ErbB-2 protein
in sera and tumors of breast cancer patients 261-270

ErbB-2 protein (continued)
overexpression, phosphorylation of p52 Shc, reduced p66 Shc 119-128
estrogen receptor
double-stranded DNA decoys reduce ER gene expression 227-235
in adjuvant chemo, endocrine, and combined regimens 51-60

fibroadenomas
low incidence of microsatellite instability and LOH 165-169
fibrotic focus
as a histopathologic prognostic factor 195-208
fractal analysis
in discriminating mammographic lesions 245-249

galectin-3
and Line 1 retrotransposon in tumorigenicity 171-183
genetic instability
low but significant LOH and microsatellite instability in fibroadenomas 165-169
grade
association with young age, p53 status 35-39

HER-2/*neu*
see ErbB-2
high-dose chemotherapy
mobilization of PBSCs for support 237-244
histamine antagonist DPPE
potentiates doxorubicin effect in pilot trial 61-68
histopathology
fibrotic focus as a prognostic factor 195-208

insulin resistance
in breast cancer risk due to Western diet, early puberty 187-193
intraductal spread
diagnostic value of contrast-enhanced CT scan 79-86

Ki-67 proliferation index
function relationship with BrdU labelling 155-164

Line 1 retrotransposon
and galectin-3 in tumorigenicity 171-183
local recurrence rates
methods for calculation amid competing endpoints 87-91
lonidamine
enhancement of doxorubicin response 209-217
loss of heterozygosity (LOH)
low incidence in fibroadenomas 165-169
lumpectomy
outcome of salvage treatments for recurrence 69-78

mammography
fractal analysis to discriminate observed lesions 245-249
menarche
and Western diet, breast cancer risk 187-193
menopausal status
in adjuvant chemo, endocrine, and combined regimens 51-60
microsatellite instability
low incidence in fibroadenomas 165-169
mifepristone
antitumor activity in vivo, especially with tamoxifen 109-117
mitomycin C
with cyclophosphamide in comparison of adjuvant chemo, endocrine, and combined regimens 51-60
MTT assay
in *in vitro* chemosensitivity determination 251-259

onapristone
antitumor activity in vivo, especially with tamoxifen 109-117

p53
association with young age through grade, nodal status 35-39
paclitaxel
phase II study with cisplatin, G-CSF 13-26
PAI-1 (plasminogen activator inhibitor-1)
and PAI-2, uPA — tissue extraction procedures 135-143
and uPA, uPAR in plasma during menstrual cycle, menopause 41-50

premalignant breast disease
low incidence of microsatellite instability and LOH in fibroadenomas 165-169
progesterone receptor
prognosis of ER–/PgR+ breast tumors 219-225
prognostic factors
association of p53 with young age through grade, nodal status 35-39
cathepsin D in bone marrow micrometastases 145-154
correction of plasma uPA, PAI-1, uPAR for menstrual cycle, menopause 41-50
ER–/PgR+ breast tumors 219-225
extraction procedures for uPA, PAI-1, and PAI-2 135-143
fibrotic focus in histopathology 195-208
functional relationship of Ki-67 and BrdU labelling 155-164
tumor cells by IHC in bone marrow biopsy 27-33
proliferation markers
Ki-67 comparison with BrdU labeling index 155-164
protein kinase A
antisense depletion of RIα subunit induces apoptosis and growth arrest 97-107

radiotherapy
and reduced local recurrence in breast conservation 69-78
risk factors
Western diet, early puberty, and breast cancer risk 187-193

Shc
phosphorylation of p52 Shc by ErbB-2 and reduced inhibitory p66 Shc 119-128
signal transduction
ErbB-2 overexpression, phosphorylated p52 Shc, and reduced p66 Shc 119-128
statistical methods
calculation of local recurrence rates amid competing endpoints 87-91
stem cell support
regimen for mobilization of peripheral blood stem cells 237-244

tamoxifen
antitumor activity enhanced with antiprogestins 109-117
taxol
see paclitaxel
transcriptional specific intervention
double-stranded DNA decoys reduce ER gene expression 227-235

uPA (urokinase-type plasminogen activator)
and PAI-1, PAI-2 tissue extraction procedures 135-143
and PAI-1, uPAR in plasma during menstrual cycle, menopause 41-50

vinorelbine
trial of combination with epirubicin as first line therapy 129-134